Evommune Announces Pricing of its Initial Public Offering
Evommune, Inc. (EVMN)
Company Research
Source: PR Newswire
PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share. In addition, Evommune has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to Evommune from the initial public offering, without giving effect to the underwriters' option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses, are expected to be $150 million. The shares are expected to begin trading on the New York Stock Exchange on November 6, 2025 under the symbol "EVMN."
Show less
Read more
Impact Snapshot
Event Time:
EVMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVMN alerts
High impacting Evommune, Inc. news events
Weekly update
A roundup of the hottest topics
EVMN
News
- Evommune (NYSE:EVMN) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- Evommune (NYSE:EVMN) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Evommune (NYSE:EVMN) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Evommune (NYSE:EVMN) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $42.00 price target on the stock.MarketBeat
- Evommune (NYSE:EVMN) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
EVMN
Sec Filings
- 11/17/25 - Form SCHEDULE
- 11/17/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- EVMN's page on the SEC website